查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1747034

日本生物製药市场报告（按适应症（自体免疫疾病、肿瘤学、代谢紊乱等）、类别（重组蛋白、单株抗体、纯化蛋白）和地区划分，2025 年至 2033 年）

Japan Biopharmaceutical Market Report by Indication (Autoimmune Diseases, Oncology, Metabolic Disorders, and Others), Class (Recombinant Proteins, Monoclonal Antibodies, Purified Proteins), and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 120 Pages | 商品交期: 5-7个工作天内

价格
简介目录

2024年，日本生物製药市场规模达235亿美元。展望未来， IMARC Group预计到2033年，市场规模将达到358亿美元，2025-2033年期间的复合年增长率（CAGR）为4.56%。市场成长主要源自于几个关键因素，包括客製化药物需求的不断增长、慢性病和生活方式相关疾病发病率的上升，以及生物技术的快速进步，尤其是在基因工程和重组DNA技术等领域。

生物製药，也称为生物製剂，属于源自生物来源的一类药物。这些药物是透过生物技术製程利用细菌、酵母或哺乳动物细胞等活体生物体製造的。与传统的化学合成小分子药物相比，生物製药的特征是其分子结构庞大且复杂，这使得它们能够与体内的生物靶点进行高度精确的相互作用。生物製药比传统药物具有许多优势。它们的作用通常具有显着的特异性，通常靶向特定的受体或分子。这种特异性通常可以提高疗效并减少不良副作用。此外，生物製药可望治疗那些传统药物难以攻克的疾病。

日本生物製药市场趋势：

在日本，多种因素推动了市场的大幅成长。首先，个人化医疗的需求显着成长，这是一个重要的驱动因素。此外，生物製药在治疗癌症、糖尿病、牛皮癣和类风湿性关节炎等疾病方面的应用日益广泛，也是推动这一增长的另一个关键因素。此外，公众对生物製药的有效性和可近性的认识不断提高，进一步推动了区域市场的发展。此外，人们更重视罕见疾病的治疗和孤儿药的开发，这也推动了市场的成长。这些罕见疾病通常患者人数较少，存在着巨大的未满足的医疗需求。此外，政府和监管机构推出了激励措施并简化了监管流程，以鼓励开发针对这些疾病的疗法，这也是另一个重要的成长诱因。此外，生物製药公司正在积极投资研发，以开发针对罕见疾病的孤儿药。这种方法不仅满足了关键的医疗需求，也为预测期内的市场扩张创造了机会。

日本生物製药市场细分：

指示见解：

  • 自体免疫疾病
  • 肿瘤学
  • 代谢紊乱
  • 其他的

课堂见解：

  • 重组蛋白
  • 单株抗体
  • 纯化蛋白质

竞争格局：

市场研究报告也对竞争格局进行了全面的分析。报告涵盖了市场结构、关键参与者定位、最佳制胜策略、竞争仪錶板和公司评估象限等竞争分析。此外，报告还提供了所有主要公司的详细资料。

本报告回答的关键问题：

  • 日本生物製药市场迄今表现如何？未来几年将如何表现？
  • COVID-19 对日本生物製药市场有何影响？
  • 日本生物製药市场依适应症划分是怎样的？
  • 日本生物製药市场依类别划分是怎样的？
  • 日本生物製药市场的价值链分为哪些阶段？
  • 日本生物製药的关键驱动因素和挑战是什么？
  • 日本生物製药市场的结构是怎么样的？主要参与者是谁？
  • 日本生物製药市场的竞争程度如何？

本报告回答的关键问题：

  • 日本生物製药市场迄今表现如何？未来几年将如何表现？
  • COVID-19 对日本生物製药市场有何影响？
  • 日本生物製药市场依适应症划分是怎样的？
  • 日本生物製药市场依类别划分是怎样的？
  • 日本生物製药市场的价值链分为哪些阶段？
  • 日本生物製药的关键驱动因素和挑战是什么？
  • 日本生物製药市场的结构是怎么样的？主要参与者是谁？
  • 日本生物製药市场的竞争程度如何？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：日本生物製药市场 - 简介

  • 概述
  • 市场动态
  • 产业趋势
  • 竞争情报

第五章：日本生物製药市场格局

  • 历史与当前市场趋势（2019-2024）
  • 市场预测（2025-2033）

第六章：日本生物製药市场-细分：按适应症

  • 自体免疫疾病
    • 概述
  • 肿瘤学
    • 概述
  • 代谢紊乱
    • 概述
  • 其他的

第七章：日本生物製药市场-分类：依类别

  • 重组蛋白
    • 概述
  • 单株抗体
    • 概述
  • 纯化蛋白质
    • 概述

第八章：日本生物製药市场-竞争格局

  • 概述
  • 市场结构
  • 市场参与者定位
  • 最佳获胜策略
  • 竞争仪錶板
  • 公司评估象限

第九章：关键参与者简介

  • Company A
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company B
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company C
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company D
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company E
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events

第十章：日本生物製药市场-产业分析

  • 驱动因素、限制因素和机会
    • 概述
    • 驱动程式
    • 限制
    • 机会
  • 波特五力分析
    • 概述
    • 买家的议价能力
    • 供应商的议价能力
    • 竞争程度
    • 新进入者的威胁
    • 替代品的威胁
  • 价值链分析

第 11 章：附录

简介目录
Product Code: SR112025A18367

Japan biopharmaceutical market size reached USD 23.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 35.8 Billion by 2033, exhibiting a growth rate (CAGR) of 4.56% during 2025-2033. The market is experiencing growth due to several key factors, including an increasing need for customized medicines, the rising incidence of chronic and lifestyle-related illnesses, and rapid advancements in biotechnology, particularly in areas like genetic engineering and recombinant DNA technology.

Biopharmaceuticals, also referred to as biologics, belong to a category of pharmaceutical medications that originate from biological sources. These drugs are manufactured through biotechnological processes utilizing living organisms such as bacteria, yeast, or mammalian cells. In contrast to conventional small-molecule drugs synthesized chemically, biopharmaceuticals are characterized by their large and intricate molecular structures, which allow them to engage in highly precise interactions with biological targets within the body. Biopharmaceuticals offer numerous advantages over traditional pharmaceuticals. They often demonstrate a remarkable degree of specificity in their action, frequently targeting particular receptors or molecules. This specificity typically leads to enhanced effectiveness and a reduction in adverse side effects. Moreover, biopharmaceuticals hold the potential to treat diseases that were historically challenging to address using conventional drug approaches.

Japan Biopharmaceutical Market Trends:

In Japan, several factors are contributing to substantial market growth. Firstly, there is a notable surge in demand for personalized medicine, which is a significant driver. Additionally, the increased adoption of biopharmaceuticals for treating conditions such as cancer, diabetes, psoriasis, and rheumatoid arthritis is another key factor fueling this growth. Furthermore, there is a growing awareness among the general population regarding the effectiveness and accessibility of biopharmaceuticals, further propelling the regional market. Moreover, there is a heightened focus on addressing rare diseases and developing orphan drugs, which is driving market growth. These rare diseases, often characterized by small patient populations, present significant unmet medical needs. Besides this, governments and regulatory agencies have introduced incentives and streamlined regulatory processes to encourage the development of therapies for these conditions, which is acting as another significant growth-inducing factor. Furthermore, biopharmaceutical companies are actively investing in research and development (R&D) efforts to create orphan drugs targeting rare diseases. This approach not only addresses critical medical needs but also creates opportunities for expanding the market over the forecasted period.

Japan Biopharmaceutical Market Segmentation:

Indication Insights:

  • Autoimmune Diseases
  • Oncology
  • Metabolic Disorders
  • Others

Class Insights:

  • Recombinant Proteins
  • Monoclonal Antibodies
  • Purified Proteins

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

  • How has the Japan biopharmaceutical market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan biopharmaceutical market?
  • What is the breakup of the Japan biopharmaceutical market on the basis of indication?
  • What is the breakup of the Japan biopharmaceutical market on the basis of class?
  • What are the various stages in the value chain of the Japan biopharmaceutical market?
  • What are the key driving factors and challenges in the Japan biopharmaceutical?
  • What is the structure of the Japan biopharmaceutical market and who are the key players?
  • What is the degree of competition in the Japan biopharmaceutical market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Biopharmaceutical Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Biopharmaceutical Market Landscape

  • 5.1 Historical and Current Market Trends (2019-2024)
  • 5.2 Market Forecast (2025-2033)

6 Japan Biopharmaceutical Market - Breakup by Indication

  • 6.1 Autoimmune Diseases
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2019-2024)
    • 6.1.3 Market Forecast (2025-2033)
  • 6.2 Oncology
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2019-2024)
    • 6.2.3 Market Forecast (2025-2033)
  • 6.3 Metabolic Disorders
    • 6.3.1 Overview
    • 6.3.2 Historical and Current Market Trends (2019-2024)
    • 6.3.3 Market Forecast (2025-2033)
  • 6.4 Others
    • 6.4.1 Historical and Current Market Trends (2019-2024)
    • 6.4.2 Market Forecast (2025-2033)

7 Japan Biopharmaceutical Market - Breakup by Class

  • 7.1 Recombinant Proteins
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2019-2024)
    • 7.1.3 Market Forecast (2025-2033)
  • 7.2 Monoclonal Antibodies
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2019-2024)
    • 7.2.3 Market Forecast (2025-2033)
  • 7.3 Purified Proteins
    • 7.3.1 Overview
    • 7.3.2 Historical and Current Market Trends (2019-2024)
    • 7.3.3 Market Forecast (2025-2033)

8 Japan Biopharmaceutical Market - Competitive Landscape

  • 8.1 Overview
  • 8.2 Market Structure
  • 8.3 Market Player Positioning
  • 8.4 Top Winning Strategies
  • 8.5 Competitive Dashboard
  • 8.6 Company Evaluation Quadrant

9 Profiles of Key Players

  • 9.1 Company A
    • 9.1.1 Business Overview
    • 9.1.2 Services Offered
    • 9.1.3 Business Strategies
    • 9.1.4 SWOT Analysis
    • 9.1.5 Major News and Events
  • 9.2 Company B
    • 9.2.1 Business Overview
    • 9.2.2 Services Offered
    • 9.2.3 Business Strategies
    • 9.2.4 SWOT Analysis
    • 9.2.5 Major News and Events
  • 9.3 Company C
    • 9.3.1 Business Overview
    • 9.3.2 Services Offered
    • 9.3.3 Business Strategies
    • 9.3.4 SWOT Analysis
    • 9.3.5 Major News and Events
  • 9.4 Company D
    • 9.4.1 Business Overview
    • 9.4.2 Services Offered
    • 9.4.3 Business Strategies
    • 9.4.4 SWOT Analysis
    • 9.4.5 Major News and Events
  • 9.5 Company E
    • 9.5.1 Business Overview
    • 9.5.2 Services Offered
    • 9.5.3 Business Strategies
    • 9.5.4 SWOT Analysis
    • 9.5.5 Major News and Events

10 Japan Biopharmaceutical Market - Industry Analysis

  • 10.1 Drivers, Restraints, and Opportunities
    • 10.1.1 Overview
    • 10.1.2 Drivers
    • 10.1.3 Restraints
    • 10.1.4 Opportunities
  • 10.2 Porters Five Forces Analysis
    • 10.2.1 Overview
    • 10.2.2 Bargaining Power of Buyers
    • 10.2.3 Bargaining Power of Suppliers
    • 10.2.4 Degree of Competition
    • 10.2.5 Threat of New Entrants
    • 10.2.6 Threat of Substitutes
  • 10.3 Value Chain Analysis

11 Appendix